<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639650</url>
  </required_header>
  <id_info>
    <org_study_id>ZJHGTN1211</org_study_id>
    <nct_id>NCT02639650</nct_id>
  </id_info>
  <brief_title>Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor</brief_title>
  <official_title>A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weiguo Lv</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Zhongshan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's Hospital School Of Medicine Zhejiang University</source>
  <brief_summary>
    <textblock>
      This clinical trial is designed to study the effect and safety of paclitaxel plus cisplatin
      as the first-line regimen in the treatment of high risk gestational trophoblastic tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate in firstline treatment</measure>
    <time_frame>2 years</time_frame>
    <description>We may calculate the rate of complete response and the rate of treatment failure at the preliminary end point of the trail.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events as assessed by the WHO</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate (OR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian functional evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>We may record the age of menopause to evaluate the the function of ovary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian functional evaluation</measure>
    <time_frame>every 6 months up to 3 years</time_frame>
    <description>We may test serum level of anti-mullerian hormone (AMH) every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian functional evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>We may record the time of menstrual cycle resuming after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pregnancy rate</measure>
    <time_frame>3 years</time_frame>
    <description>To calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Gestational Trophoblastic Neoplasms</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel + cisplatin or carboplatin，two weeks a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>actinomycin D</intervention_name>
    <description>actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who International Federation of Gynecology and Obstetrics (FIGO) Stage I, II,
             or III criteria for high-risk gestational trophoblastic neoplasia (GTN) and stage Ⅳ
             cases

          -  World Health Organization(WHO) risk score ≥7

          -  Age≤60 years; female, Chinese women

          -  Initial treatment is chemotherapy

          -  Performance status: Karnofsky score≥60

          -  Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤
             1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of
             normal,blood urea nitrogen, Cr≤ normal

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Patients with unconfirmed diagnosis of GTN

          -  Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic
             tumor (ETT)

          -  WHO risk score 《7

          -  With severe or uncontrolled internal disease, unable to receive chemotherapy

          -  Concurrently participating in other clinical trials

          -  Unable or unwilling to sign informed consents

          -  Unable or unwilling to abide by protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>December 20, 2015</last_update_submitted>
  <last_update_submitted_qc>December 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Women's Hospital School Of Medicine Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weiguo Lv</investigator_full_name>
    <investigator_title>Vice-President</investigator_title>
  </responsible_party>
  <keyword>gestational trophoblastic tumor</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

